ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0753

Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System

Jeremy Sullivan1, Anna Ware2, Gary Tarasovsky3, Cherish Wilson4, Mary Whooley3, Jasvinder Singh5, Jinoos Yazdany6 and Gabriela Schmajuk4, 1University of California San Francisco, San Francisco, CA, 2Palo Alto VA, Minneapolis, MN, 3San Francisco VA, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: gout, quality of care, race/ethnicity, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Measures & Measurement of Healthcare Quality

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe cutaneous adverse events. However, no data exists on population-wide genetic testing rates. We investigated HLA-B*58:01 testing among allopurinol users in the Veterans Health Administration (VHA) Healthcare System.

Methods: Using data from the VHA Corporate Data Warehouse (CDW), we identified facilities with structured fields available for capturing HLA-B*58:01 test results. From these facilities, we identified all patients with a current, active prescription for allopurinol as of December 2022. We assessed the proportion of patients with a documented HLA-B*58:01 test at any time within the CDW, by race or ethnicity. We repeated this analysis among incident users of allopurinol (defined as users with a prescription in 2022 and no allopurinol use in the preceding 3 years). Finally, we examined variation in HLA-B*58:01 testing among self-identified Asian or Black patients by VHA facility, among facilities with ≥ 20 eligible patients. We contacted the top performing facility to learn about local workflows for obtaining genetic testing for allopurinol users.

Results: Only 40 out of 130 facilities had a structured field available for capturing HLA-B*58:01 test results. We identified 79,361 users of allopurinol at these facilities; 98% of them were male, and mean age was 70 years (SD 12). Among prevalent users, 13.8% of Asian and 2.4% of Black patients were ever tested for the HLA-B*58:01 allele (Table). Among incident users, testing was documented among 10.1% of Asian and 3.0% of Black patients. We observed wide variation in HLA-B*58:01 testing across facilities (range 0% – 42.0%; Figure). The top-performing facility (proportion tested 42.0%) relayed that they had developed an allopurinol order set and pharmacy workflow that prevented allopurinol prescribing prior to completion of genetic testing.

Conclusion: Across the VHA Healthcare System, testing for HLA-B*58:01 in high-risk groups was very low, and variation across facilities was high. Most facilities lack a structured field for HLA-B*58:01 results, which hinders measurement of quality gaps. In order to improve testing rates, facilities should consider implementing order sets or pharmacy “hard stops” that require HLA-B*58:01 testing for high-risk groups.

Supporting image 1

Supporting image 2


Disclosures: J. Sullivan: None; A. Ware: None; G. Tarasovsky: None; C. Wilson: None; M. Whooley: None; J. Singh: Other, 2, 6, 11, 11, 12, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web, 12, Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, 12, speaker’s bureau of Simply Speaking, other, 12, received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec, Other, 12, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam; J. Yazdany: AstraZeneca, 2, 5, Aurinia, 5, Gilead, 5, Pfizer, 2; G. Schmajuk: None.

To cite this abstract in AMA style:

Sullivan J, Ware A, Tarasovsky G, Wilson C, Whooley M, Singh J, Yazdany J, Schmajuk G. Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/facility-variation-in-hla-b5801-allele-testing-for-asian-and-black-patients-receiving-allopurinol-in-the-veterans-affairs-healthcare-system/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facility-variation-in-hla-b5801-allele-testing-for-asian-and-black-patients-receiving-allopurinol-in-the-veterans-affairs-healthcare-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology